Welcome to Britannia Pharmaceuticals Ltd

Science & innovation
Our Science
For more than 30 years, our primary field of interest has been the development of innovative, patient-centric technology that effectively delivers therapies to people with Parkinson’s disease.
We work with specialist focus groups, fund clinical trials and invest in care initiatives that optimise treatment programmes to improve quality of life.

Therapies
Therapeutic Focus
Britannia Pharmaceuticals Ltd. is dedicated to improving the lives of people with long-term neurological conditions, and providing important support for their families, caregivers, and medical teams.
We offer world-leading medications to improve disease management and quality-of-life for patients, as well as supporting treatment programmes for patients, families, and carers that provide extra assistance in managing these conditions.
Explore the latest with Britannia
Read Our Latest News
International
The STADA Group
As part of the STADA group, we operate in over 30 countries worldwide, and are the global Parkinson’s Disease centre.